Kyver­na seeks $182M IPO as biotech runs mul­ti­ple au­toim­mune CAR-T tri­als

Kyver­na Ther­a­peu­tics aims to be the fifth biotech to IPO in 2024 as the au­toim­mune CAR-T cell ther­a­py mak­er sets its sights on $182 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.